TP53 and neoplasm: Another murine model utilizing human neural stem and progenitor cells harboring transformed c-MYC, dominant-negative p53, and constitutively active AKT and hTERT revealed tumor sensitivity to cyclin-dependent kinase (CDK) inhibitors, such as palbociclib [66].